-transparent.png){kind=logo}
BACKGROUND Buspirone is used as a neuroendocrine challenge in which the increase of circulating prolactin is taken as a measure of the sensitivity of central serotonergic (5-HT(1A)) pathways. Interpretation of the test is complicated, however, by the fact that buspirone possesses D(2) antagonist and 5-HT(1A) agonist activity, both of which will result in the release of prolactin. To understand the significance of prolactin secretion in response to buspirone, it is important to measure the differential actions of the two controlling pathways. OBJECTIVE To characterise the dual action of buspirone in stimulating the secretion of prolactin by blocking the 5-HT(1A) action with the 5-HT1A antagonist action of pindolol. METHODS Healthy male subjects (n=35) received buspirone (0.5 mg x kg bw(-1) orally) with and without pre-treatment with the 5-HT(1A) receptor antagonist pindolol (40 mg over 2 days, 0.5 mg x kg bw(-1) on test day). Nine subjects underwent two additional trials in which they received a placebo with and without pre-treatment with pindolol. RESULTS Pindolol alone caused a small but significant reduction (18%) in the tonic release of prolactin. Buspirone alone produced a robust prolactin response which was reduced to approximately half by pindolol pre-treatment. Pindolol pre-treatment also, on average, delayed the onset and peak of the prolactin response. There was wide variation among individuals both in the absolute response to buspirone and in the proportion that could be attributed to the non-serotonergic agonist action of buspirone (22-82% IQ range). CONCLUSIONS Our results indicate that while serotonergic pathways play a minor role in the tonic release of prolactin, the response to a buspirone challenge alone cannot be used as a simple index of central serotonergic activity. However, if two challenges are carried out, one with buspirone and the other with buspirone plus pindolol, quantitative measures can be made of the sensitivity of both the 5-HT(1A) and the putative D(2) pathways controlling prolactin release.
M W Bridge, and
G Marvin, and
C E Thompson, and
A Sharma, and
D A Jones, and
M J Kendall
January 1992,
Psychopharmacology,
M W Bridge, and
G Marvin, and
C E Thompson, and
A Sharma, and
D A Jones, and
M J Kendall
April 2016,
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
M W Bridge, and
G Marvin, and
C E Thompson, and
A Sharma, and
D A Jones, and
M J Kendall
September 2014,
Pakistan journal of pharmaceutical sciences,
M W Bridge, and
G Marvin, and
C E Thompson, and
A Sharma, and
D A Jones, and
M J Kendall
June 2009,
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,
M W Bridge, and
G Marvin, and
C E Thompson, and
A Sharma, and
D A Jones, and
M J Kendall
August 1993,
European journal of pharmacology,
M W Bridge, and
G Marvin, and
C E Thompson, and
A Sharma, and
D A Jones, and
M J Kendall
July 2012,
Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus,
M W Bridge, and
G Marvin, and
C E Thompson, and
A Sharma, and
D A Jones, and
M J Kendall
January 1991,
Journal of neural transmission. General section,
M W Bridge, and
G Marvin, and
C E Thompson, and
A Sharma, and
D A Jones, and
M J Kendall
March 2005,
Pharmacology,
M W Bridge, and
G Marvin, and
C E Thompson, and
A Sharma, and
D A Jones, and
M J Kendall
March 2017,
Doklady biological sciences : proceedings of the Academy of Sciences of the USSR, Biological sciences sections,
M W Bridge, and
G Marvin, and
C E Thompson, and
A Sharma, and
D A Jones, and
M J Kendall
June 1997,
Methods and findings in experimental and clinical pharmacology,
